These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 9819047)

  • 1. Recombinant activated factor VII as a universal haemostatic agent.
    Hedner U
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S147-52. PubMed ID: 9819047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NovoSeven as a universal haemostatic agent.
    Hedner U
    Blood Coagul Fibrinolysis; 2000 Apr; 11 Suppl 1():S107-11. PubMed ID: 10850574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levels of prothrombin activation peptide F1+2 in patients with a bleeding tendency.
    Ingerslev J; Holm M; Christiansen K; Knudsen L; Négrier C
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S129-34. PubMed ID: 9819044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elective surgery in patients with congenital coagulopathies and inhibitors: experience of the National Haemophilia Centre of Venezuela.
    Boadas A; Fernández-Palazzi F; De Bosch NB; Cedeño M; Ruiz-Sáez A
    Haemophilia; 2011 May; 17(3):422-7. PubMed ID: 21118333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
    Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
    Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. General haemostatic agents--fact or fiction?
    Hedner U
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():33-6. PubMed ID: 12214145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII.
    Hoffman M; Monroe DM; Roberts HR
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S61-5. PubMed ID: 9819030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders.
    Birschmann I; Klamroth R; Eichler H; Schenk J; Kirchmaier CM; Halimeh S
    Haemophilia; 2013 Sep; 19(5):679-85. PubMed ID: 23647644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant activated factor VIIa in uncontrolled bleeding: a haemostasis laboratory study in non-haemophilia patients.
    Brandsborg S; Sørensen B; Poulsen LH; Ingerslev J
    Blood Coagul Fibrinolysis; 2006 Jun; 17(4):241-9. PubMed ID: 16651865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease.
    Razon Y; Erez E; Vidne B; Birk E; Katz J; Tamari H; Dagan O
    Paediatr Anaesth; 2005 Mar; 15(3):235-40. PubMed ID: 15725322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Use of recombinant activated factor VII].
    Reingardiene D; Lazauskas R
    Medicina (Kaunas); 2009; 45(3):248-53. PubMed ID: 19357455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical use of recombinant FVIIa (rFVIIa).
    Hedner U; Ingerslev J
    Transfus Sci; 1998 Jun; 19(2):163-76. PubMed ID: 10187041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant activated factor VII: 30 years of research and innovation.
    Hedner U
    Blood Rev; 2015 Jun; 29 Suppl 1():S4-8. PubMed ID: 26073368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. To general haemostasis--the evidence-based route.
    Erhardtsen E
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():47-52. PubMed ID: 12214148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigenicity of activated recombinant factor VII followed through nine years of clinical experience.
    Nicolaisen EM
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S119-23. PubMed ID: 9819042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Recombinant factor VIIa in patients with platelet function disorders or thrombocytopenia].
    Zotz RB; Scharf RE
    Hamostaseologie; 2007 Sep; 27(4):251-62. PubMed ID: 17938763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential role of recombinant factor VIIa as a hemostatic agent.
    Hedner U; Erhardtsen E
    Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant activated factor VII (rFVIIa) treatment in infants with hemorrhage.
    Brady KM; Easley RB; Tobias JD
    Paediatr Anaesth; 2006 Oct; 16(10):1042-6. PubMed ID: 16972833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, efficacy and cost-effectiveness of home therapy with recombinant activated factor VII in a patient with severe haemophilia A and an anti-factor VIII inhibitor.
    Stewart AJ; Hanley JP; Ludlam CA
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S93-5. PubMed ID: 9819036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
    Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
    Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.